Review of 12 human studies on salvinorin A: fast, short effects and no serious harms

The question

What do human studies actually show about how salvinorin A, the active compound in Salvia divinorum, behaves in the body, what it does to mind and body, and how safe it appears to be?

What they did

Researchers searched three large research databases (PubMed, Web of Science and EMBASE) from their start dates up to 18 January 2026 for human studies of salvinorin A. They included 12 clinical trials with 174 participants in total. Most trials enrolled medically healthy volunteers who had used hallucinogens before, and gave salvinorin A by inhalation at doses of 0.375-21 µg/kg (0.2-12 mg). The authors summarized how the drug moved through the body, its psychological and physical effects, and reported harms.

What they found

Inhaled salvinorin A acted within seconds, peaked at 1-2 minutes, and effects resolved within 30 minutes. Two studies used a form placed under the tongue, which had a slower start and longer duration, while one study found that swallowing it produced no effect. No serious adverse events were reported across the included trials. Vital signs were mostly stable, with occasional mild rises in blood pressure or heart rate. Some participants experienced disorientation, anxiety and distress during the acute effects, while others reported positive subjective changes. Long-term adverse effects were rare and the potential for misuse appeared low.

The fine print

Only 12 trials with 174 people in total were available, and the individual studies were small and varied in design and dosing. Most participants were healthy volunteers who already had experience with hallucinogens, so the findings may not apply to patients or to first-time users. The review describes short-term laboratory effects, not treatment of any condition, and follow-up for long-term outcomes was limited. This summary is based on the abstract alone.

What it means

In controlled laboratory settings, salvinorin A produced very brief and intense effects without serious physical harm, but the evidence base is small and there is no evidence yet that it treats any condition.

Evidence grade: Low. A systematic review of 12 small human trials, mostly in healthy, hallucinogen-experienced volunteers, with no pooled statistical analysis and no clinical outcomes in patient groups.

This summary is based on the study’s published abstract.